US EditionWHO Endorses Twice-Yearly Lenacapavir Injections for HIV Prevention
LOW- AND MIDDLE-INCOME COUNTRIES, JUL 14 – Gilead and the Global Fund will provide lenacapavir injections at no profit to reach 2 million people in low- and middle-income countries over three years, expanding HIV prevention access.
- The WHO on Monday recommended twice-yearly lenacapavir injections as an additional HIV prevention option at IAS 2025 in Kigali, Rwanda.
- Following trial results showing 99.9% HIV transmission reduction, WHO recommends biannual lenacapavir injections amid rising concerns over global HIV prevention funding cuts.
- Under the new deal, the Global Fund will purchase and distribute lenacapavir doses at no profit, covering up to 2 million people in LMICs.
- Despite the agreement, it remains unclear if the Global Fund can fully fund all doses as US aid withdrawals and PEPFAR’s future remain unresolved.
- The UN warns that without sustained funding, millions more could die of HIV by 2029, as 80% of prevention efforts in LMICs depend on international aid.
52 Articles
52 Articles
By Jacqueline Howard, CNN The World Health Organization (WHO) now recommends that countries include lenacapavir for the prevention of human immunodeficiency virus (HIV). The newly approved drug is a tool in its efforts to combat HIV infections, especially for groups at greatest risk and in areas where the HIV burden remains high. The global recommendation, issued Monday at the International AIDS Conference in Kigali, Rwanda, comes about a month …
'Since it's the drug capital, at least it's done safely.'
WHO-recommended lenacapavir could offer a path toward an HIV-free world, but only if people can access it
WHO-recommended lenacapavir could offer a path toward an HIV-free world, but only if people can access it Amid global funding cuts, MSF is deeply concerned about people’s access to this game-changing HIV prevention medicine. Kate Rankin July 14 2025, 9:55am The developer, Gilead Sciences, must now make it more accessible for people all over the world, said MSF. Access to this form of HIV prevention—an injectable version of pre-exposure prophyl…
Coverage Details
Bias Distribution
- 89% of the sources are Center
To view factuality data please Upgrade to Premium
